Specificity of treatment is mandatory in very old patients with hairy cell leukemia
Abstract
Introduction. There are only a few available data about hairy cell leukemia (HCL) in very old patients. We presented three very different cases of HCL in very old patients diagnosed in a single center and discussed some epidemiological and therapeutical issues in such patients. Case report. The first patient, 89-year-old, had symptomatic cytopenia and achieved sustained complete remission after cladribine treatment. The second patient, 89-year-old, had asymptomatic disease with stable full blood counts during a 3-year follow-up period in which watch-and-wait policy was adopted. The third patient, 82 years old, had two malignancies (HCL and presumably metastatic colorectal carcinoma) and his only treatment were occasional red blood cell transfusions and symptomatic therapy. Conclusion. The presented illustrative examples confirm individualization of treatment is mandatory in very old patients with HCL.
References
Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: A clinical review based on 71 cases. Ann Intern Med 1978; 89(5 Pt 1): 677−83.
Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 1984; 11(4 Suppl 2): 458−71.
Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 2012; 156(2): 186−95.
Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993; 85(4): 714−7.
Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007; 99(3): 215−22.
Juliusson G, Samuelsson H. Swedish Lymphoma Registry. Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. Leuk Lymphoma 2011; 2(Suppl 2): 46−9.
Kristinsson SY, Vidarsson B, Agnarsson BA, Haraldsdottir V, Olafsson O, Johannesson GM, et al. Epidemiology of hairy cell leukemia in Iceland. Hematol J 2002; 3(3): 145−7.
Gotić M. The importance of the immune phenotype of leukemic cells in patients with hairy cell leukemia [thesis]. Belgrade: Faculty of Medicine, University of Belgrade; 1998. (Serbian)
Department of Economic and Social Affairs population Division. World Population ageing: 1950−2050. New York: United Nations; 2001.
Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17(1): 45−51.
Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladri-bine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145(6): 733−40.
Salemis NS, Pinialidis D, Tsiambas E, Gakis C, Nakos G, Samba-ziotis D, et al. Synchronous occurrence of neuroendocrine co-lon carcinoma and hairy cell leukemia. J Gastrointest Cancer 2011; 42(3): 131−6.
Perunicic-Jovanovic M, Djunic I, Tomin D, Terzic T, Jakovic L, Sokic A, et al. Simultaneous Presentation of Hairy Cell Leukemia and Metastatic Signet Ring Carcinoma of the Stomach Diagnosed by Bone Marrow Biopsy. Appl Immunohistochem Mol Morphol 2011; 19(3): 279−82.
Aydin SO, Eskazan AE, Aki H, Ozguroglu M, Baslar Z, Soysal T. Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. Case Rep Oncol 2011; 4(3): 439−44.